blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP3526255

EP3526255 - ANTI-LAG-3 ANTIBODIES AND COMPOSITIONS [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  05.10.2022
Database last updated on 15.06.2024
FormerRequest for examination was made
Status updated on  19.07.2019
FormerThe international publication has been made
Status updated on  20.04.2018
Formerunknown
Status updated on  10.11.2017
Most recent event   Tooltip28.10.2023New entry: Renewal fee paid 
Applicant(s)For all designated states
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
No.369 Yuzhou South Rd.
Lianyungang City, Jiangsu 222062 / CN
[2022/44]
Former [2019/34]For all designated states
Symphogen A/S
Pederstrupvej 93
2750 Ballerup / DK
Inventor(s)01 / GRANDAL, Michael Monrad
Solbrinken 26a
2750 Ballerup / DK
02 / BHATIA, Vikram Kjøller
Hovmarksvej 31
2920 Charlottenlund / DK
03 / GJETTING, Torben
Vibevej 7
4040 Jyllinge / DK
04 / FRÖHLICH, Camilla
Nøjsomhedsvej 13. 2. th
2100 København Ø / DK
05 / GALLER, Gunther Roland
Solsikkevej 17
4040 Jyllinge / DK
06 / KRAGH, Michael
Læssøesgade 1A5 Tv
2200 Copenhagen N / DK
07 / HORAK, Ivan David
21 Cliff Street
West Orange, NJ 07052 / US
08 / BOUQUIN, Thomas
Kirkeltevej 44
3450 Alleroed / DK
09 / PEDERSEN, Mikkel Wandahl
Forelvej 17
3450 Alleroed / DK
 [2019/34]
Representative(s)Pohlman, Sandra M.
df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Theatinerstrasse 16
80333 München / DE
[2019/34]
Application number, filing date17791987.513.10.2017
[2019/34]
WO2017EP76188
Priority number, dateUS201662407678P13.10.2016         Original published format: US 201662407678 P
[2019/34]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2018069500
Date:19.04.2018
Language:EN
[2018/16]
Type: A2 Application without search report 
No.:EP3526255
Date:21.08.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 19.04.2018 takes the place of the publication of the European patent application.
[2019/34]
Search report(s)International search report - published on:EP03.01.2019
ClassificationIPC:C07K16/28
[2019/34]
CPC:
C07K16/2803 (EP,CN,IL,KR,RU,US); A61K39/395 (IL,RU); A61K9/0019 (IL,US);
A61P35/00 (EP,IL,KR,RU,US); A61P37/00 (EP,IL,KR,RU); A61P37/04 (EP,IL,RU,US);
A61P43/00 (EP,IL); C12N15/85 (IL,US); A61K2039/505 (KR);
C07K2317/21 (EP,IL,KR); C07K2317/24 (EP,IL,KR); C07K2317/33 (EP,IL,KR);
C07K2317/34 (EP,IL,KR); C07K2317/51 (CN); C07K2317/515 (CN);
C07K2317/52 (EP,IL,KR); C07K2317/565 (CN); C07K2317/71 (EP,IL,KR);
C07K2317/76 (EP,IL,KR) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/34]
Extension statesBA07.05.2019
ME07.05.2019
Validation statesMA07.05.2019
MD07.05.2019
TitleGerman:ANTI-LAF-3-ANTIKÖRPER-ZUSAMMENSETZUNGEN[2019/34]
English:ANTI-LAG-3 ANTIBODIES AND COMPOSITIONS[2019/34]
French:ANTICORPS ANTI-LAG-3 ET COMPOSITIONS[2019/34]
Entry into regional phase07.05.2019National basic fee paid 
07.05.2019Designation fee(s) paid 
07.05.2019Examination fee paid 
Examination procedure07.05.2019Amendment by applicant (claims and/or description)
07.05.2019Examination requested  [2019/34]
07.05.2019Date on which the examining division has become responsible
26.07.2022Despatch of a communication from the examining division (Time limit: M02)
05.10.2022Reply to a communication from the examining division
26.10.2022Despatch of a communication from the examining division (Time limit: M04)
06.03.2023Reply to a communication from the examining division
Fees paidRenewal fee
25.10.2019Renewal fee patent year 03
23.10.2020Renewal fee patent year 04
25.10.2021Renewal fee patent year 05
27.10.2022Renewal fee patent year 06
27.10.2023Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[I]WO2008132601  (IMMUTEP [FR], et al) [I] 1,2,9-12,16-40 * examples 1-4 *;
 [I]WO2010019570  (MEDAREX INC [US], et al) [I] 1,2,9-12,16-40 * examples 1-8 *;
 [I]US2011070238  (TRIEBEL FREDERIC [FR], et al) [I] 1,2,9-12,16-40 * examples 1-6 *;
 [I]WO2014008218  (BRISTOL MYERS SQUIBB CO [US]) [I] 1,2,9-12,16-40 * page 40, line 25 - page 45, line 4; examples 1-5 *;
 [I]WO2014140180  (GLAXOSMITHKLINE IP DEV LTD [GB]) [I] 1,2,9-12,16-40 * page 24, line 20 - page 25, line 34; examples 3,4,7 *;
 [I]WO2015138920  (NOVARTIS AG [CH], et al) [I] 1,2,9-12,16-40 * examples 1-13 *;
 [I]WO2016028672  (MERCK SHARP & DOHME [US], et al) [I] 1,2,9-12,16-40 * page 82, line 28 - page 106, line 25; examples 1-15 *;
 [A]  - FRÉDÉRIC TRIEBEL, "LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination", TRENDS IN IMMUNOLGY, (20031212), vol. 24, no. 12, page 619, XP055373990 [A] 1,2,9-12,16-40
by applicantUS4399216
 US4510245
 US4634665
 EP0216846
 EP0256055
 US4740461
 EP0323997
 EP0338841
 US4912040
 US4959455
 US4968615
 US5168062
 US5179017
 WO0009560
 US6517529
 US2014093511
 WO2015138920
    - LEFRANC et al., Dev Comp Immunol, (20030000), vol. 27, no. 1, pages 55 - 77
    - CHOTHIA; LESK, J. Mol. Biol., (19870000), vol. 196, pages 901 - 917
    - CHOTHIA et al., Nature, (19890000), vol. 342, pages 878 - 883
    - ALMAGRO; FRANSSON, Front Biosci., (20080000), vol. 13, pages 1619 - 1633
    - MAGDELAINE-BEUZELIN et al., Crit Rev.Oncol Hematol., (20070000), vol. 64, pages 210 - 225
    - LEFRANC et al., Dev. Comp Immunol., (20030000), vol. 27, pages 55 - 77
    - BURKS et al., Proc Natl Acad Sci USA, (19970000), vol. 94, pages 412 - 417
    - WU et al., Proc Natl Acad Sci USA, (19980000), vol. 95, pages 6037 - 6042
    - KIPRIYANOV et al., Human Antibodies and Hybridomas, (19950000), vol. 6, pages 93 - 101
    - KIPRIYANOV et al., Mol. Immunol., (19940000), vol. 31, pages 1047 - 1058
    - BIRD et al., Science, (19880000), vol. 242, pages 423 - 426
    - HUSTON et al., Proc. Natl. Acad. Sci. USA, (19880000), vol. 85, pages 5879 - 5883
    - MCCAFFERTY et al., Nature, (19900000), vol. 348, pages 552 - 554
    - III et al., Protein Eng., (19970000), vol. 10, pages 949 - 57
    - MARTIN et al., EMBO J., (19940000), vol. 13, pages 5303 - 9
    - HOLLIGER et al., Proc. Natl. Acad. Sci. USA, (19930000), vol. 90, pages 6444 - 6448
    - TRAUNECKER et al., EMBO J., (19910000), vol. 10, pages 3655 - 3659
    - TRAUNECKER et al., Int. J. Cancer, (19920000), vol. 7, pages 51 - 52
    - PEARSON, Methods Enzymol., (19900000), vol. 183, pages 63 - 98
    - PEARSON, Methods Mol. Biol., (20000000), vol. 132, pages 185 - 219
    - PEARSON, Methods Enzymol., (19960000), vol. 266, pages 227 - 258
    - PEARSON, J. Mol. Biol., (19980000), vol. 276, pages 71 - 84
    - OSBORN et al., J Immunol., (20130000), vol. 190, no. 4, pages 1481 - 90
    - MEIJER et al., J Mol Biol., (20060000), vol. 358, no. 3, pages 764 - 72
    - HEZAREH et al., J Virol., (20010000), vol. 75, no. 24, pages 12161 - 8
    - JONES et al., Nature, (19860000), vol. 321, no. 6069, pages 522 - 5
    - NISHIBORI et al., Mol Immunol., (20060000), vol. 43, no. 6, pages 634 - 42
    - ANGAL et al., Mol. Immunol., (19930000), vol. 30, pages 105 - 108
    - MOREIRA et al., Proteins, (20070000), vol. 68, no. 4, pages 803 - 12
    - SIVALINGAM; SHEPHERD, Mol Immunol., (20120000), vol. 51, no. 3-4, pages 304 - 92012
    - KRINGELUM et al., Mol Immunol., (20130000), vol. 53, no. 1-2, pages 24 - 34
    - HUARD et al., Proc Natl Acad Sci USA, (19970000), vol. 94, pages 5744 - 5749
    - ANDREWS et al., Immunol Rev., (20170000), vol. 276, no. 1, pages 80 - 96
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.